ANTEPAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ANTEPAR (ANTEPAR).
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
| Metabolism | Partially metabolized in the liver; some metabolites are excreted unchanged. |
| Excretion | Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water. |
| Bioavailability | Oral bioavailability is approximately 80-90% due to extensive absorption with minimal first-pass metabolism. |
| Onset of Action | Oral administration: clinical effect (paralysis of helminths) occurs within 2-4 hours; topical: not applicable. |
| Duration of Action | Single oral dose provides therapeutic levels for 12-24 hours; repeat dosing may be required for complete eradication. |
| Molecular Weight | 86.14 |
| Action Class | Antiprotozoal agents |
| Brand Substitutes | Piperazine Citrate 750mg Syrup, Avizine Syrup, Piperazine Citrate Syrup |
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
| Dosage form | TABLET |
| Renal impairment | GFR 10-50 mL/min: administer 50-75% of normal dose; GFR <10 mL/min: administer 25-50% of normal dose; hemodialysis: administer after dialysis. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: contraindicated or use with extreme caution, reduce dose by 75%. |
| Pediatric use | Children: 10-20 mg/kg/day orally in 2 divided doses; maximum 750 mg/day for <10 kg, 1.5 g/day for 10-20 kg, 2.25 g/day for 20-40 kg, 3 g/day for >40 kg. |
| Geriatric use | Elderly: initiate at lower end of dosing range; monitor renal function and adjust dose accordingly; avoid in patients with significant hepatic impairment. |
| 1st trimester | Antepar (piperazine) should be avoided in the first trimester due to the lack of adequate studies and potential for adverse fetal effects. Use only if clearly needed. |
| 2nd trimester | Limited data suggest no increased risk of major malformations in the second trimester. Use with caution and only if benefit outweighs risk. |
| 3rd trimester | Avoid near term due to possible risk of neonatal neuromuscular effects. Use only if absolutely necessary. |
Clinical note
Comprehensive clinical and safety monograph for ANTEPAR (ANTEPAR).
| Placental transfer | Piperazine crosses the placenta. In animal studies, placental transfer has been demonstrated. In humans, limited data suggest transfer with potential for fetal exposure. |
| Breastfeeding | Piperazine is excreted into breast milk in small amounts. While unlikely to cause adverse effects in infants, caution is advised. Monitor for gastrointestinal effects or neuromuscular symptoms. Consider alternative agents if possible. |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to piperazinePre-existing neurological disorders (e.g., epilepsy, chorea)Severe hepatic or renal impairment
| Precautions | Caution in patients with epilepsy or impaired renal function; may cause neurotoxicity at high doses. |
| Food/Dietary | No significant food interactions reported. Avoid alcohol as it may increase CNS side effects. Take with food if gastrointestinal upset occurs. |
| Clinical Pearls | ANTEPAR (piperazine) is a first-line treatment for ascariasis and enterobiasis. It causes neuromuscular paralysis in worms via GABA receptor agonism. Contraindicated in epilepsy and renal impairment. Monitor for neurotoxicity (ataxia, confusion) especially in children. Effective against both adult and immature worms; no need for laxatives. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. First trimester exposure may be associated with a slightly increased risk of congenital anomalies, though data are limited. Second and third trimester risks are not well-defined; use only if clearly needed. |
| Fetal Monitoring | No specific fetal monitoring required. Maternal monitoring includes observation for neurotoxic effects (e.g., dizziness, ataxia) and gastrointestinal disturbances. Renal and hepatic function should be assessed before therapy. Discontinue if signs of hypersensitivity or severe neurological symptoms occur. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies at high doses showed some spermatogenic suppression, but clinical relevance is unknown. |
| Patient Advice | Take exactly as prescribed; complete full course even if symptoms improve. · May cause dizziness or blurred vision; avoid driving until you know how the drug affects you. · Report any muscle weakness, tremors, or confusion to your doctor immediately. · For pinworm infection, all household members should be treated to prevent reinfection. · Practice strict hand hygiene and wash bed linens in hot water to reduce spread. |